AICAR
AMPK activator and AMP mimetic nucleoside
- Class
- Exercise mimetic
- Half-life
- ~1.4 hours
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Animal data primarily
Overview
AICAR is a synthetic nucleoside analog that activates AMPK — the master energy sensor inside your cells — triggering many of the same metabolic adaptations you'd see with endurance training, but without the exercise itself. The compound became famous after a 2008 Cell paper showed sedentary mice given AICAR ran 44% longer than controls, with muscle that looked genetically reprogrammed for endurance. That paper made AICAR the prototype 'exercise in a pill' and got it banned by WADA in 2009, where it remains today.
Inside cells, AICAR gets phosphorylated into ZMP, which mimics AMP and activates AMPK. Once AMPK is on, it flips a metabolic switch: glucose uptake increases, fat oxidation ramps up, mitochondrial biogenesis starts, and anabolic processes like protein synthesis via mTOR shut down. It's the energy-starvation program — the same cascade you'd trigger with a long run — delivered pharmacologically.
The problem is that all the performance data are animal-only. Clinical trials in humans tested AICAR as a cardiac protectant during surgery in the 1990s and found modest benefits but too much toxicity to justify approval. No human RCT has tested it for endurance, fat loss, or metabolic health, and the compound's effects on the brain — where AMPK activation might actually be harmful — remain poorly mapped. You're looking at a mechanistically fascinating compound with strong preclinical proof-of-concept but essentially zero controlled human data for the uses people actually want it for.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved by FDA, EMA, MHRA, or any regulator for human use. Research-market sourcing = zero oversight on purity or actual compound identity.
- Banned by WADA since 2009 under category S4.5 (Hormone and Metabolic Modulators). Detection methods exist — urinary metabolites can be distinguished from endogenous AICA-ribonucleotide.
- Clinical trials in the 1990s for cardiac protection found the compound 'highly toxic' at therapeutic doses and produced undesired metabolic effects that stopped the development program (Swinnen 2005).
+ 5 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching AICAR.
- Fasting glucose (AMPK activation can lower blood sugar — risk of hypoglycemia)
- Subjective energy & fatigue (paradoxical short-term performance drop reported during adaptation)
- Resting heart rate
- Cognitive function (AMPK activation in brain may be detrimental — rodent data suggest transient benefits only)
- Liver enzymes (ALT, AST)
- Body composition
Frequently asked questions
What is AICAR?
AMPK activator and AMP mimetic nucleoside. AICAR is a synthetic nucleoside analog that activates AMPK — the master energy sensor inside your cells — triggering many of the same metabolic adaptations you'd see with endurance training, but without the exercise itself. The compound became famous after a 2008 Cell paper showed sedentary mice given AICAR ran 44% longer than controls, with muscle that looked genetically reprogrammed for endurance. That paper made AICAR the prototype 'exercise in a pill' and got it banned by WADA in 2009, where it remains today.
How is AICAR administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of AICAR?
~1.4 hours — Short plasma half-life after IV injection; oral bioavailability < 5%.
Is AICAR approved for human use?
AICAR is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for AICAR?
Evidence tier: Animal data primarily. Narkar 2008 (Cell): 4 weeks of oral AICAR in sedentary mice increased running endurance by 44%, with upregulated oxidative metabolism genes and fiber-type shift toward type I (slow-twitch). Dose not specified in abstract but typical rodent studies use 250-500 mg/kg.
What is commonly monitored when researching AICAR?
Commonly tracked markers + signals: Fasting glucose (AMPK activation can lower blood sugar — risk of hypoglycemia), Subjective energy & fatigue (paradoxical short-term performance drop reported during adaptation), Resting heart rate, Cognitive function (AMPK activation in brain may be detrimental — rodent data suggest transient benefits only), Liver enzymes (ALT, AST), Body composition.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.